

WHO study group on tobacco product regulation

Report on the scientific basis of tobacco product regulation:
Seventh report of a WHO study group



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These publications are closely tied to the Organization's priorities, which are to prevent and control disease and ensure equitable health systems based on primary health care and health promotion for individuals and communities. This includes strengthening implementation of the WHO Framework Convention on Tobacco Control (to meet Sustainable Development Goal 3a), thereby contributing to WHO's priority of improving the lives of one billion individuals through enjoyment of better health and well-being. Progress towards better health for all requires global dissemination and exchange of information based on the knowledge and experience of all WHO's Member States and on collaboration among world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO ensures broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's publications contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of international groups of experts who provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration, in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact WHO Press, World Health Organization; 1211 Geneva 27, Switzerland; www.who.int/bookorders; tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int.

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 1 5

WHO study group on tobacco product regulation

Report on the Scientific Basis of Tobacco Product Regulation:
Seventh Report of a WHO Study Group



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco product regulation: seventh report of a WHO study group.

(WHO Technical Report Series, No. 1015)

ISBN 978-92-4-121024-9

ISSN 0512-3054

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco product regulation: seventh report of a WHO study group. Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1015). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Contents

Participants in the ninth meeting of the WHO Study Group on Tobacco Product Regulation	vii
Acknowledgements	ix
Abbreviations	x
Commentary	xi
1. Introduction	1
1.1 References	2
2. Heated tobacco products	3
2.1 Introduction	3
2.2 The science of heated tobacco products	4
2.3 A brief history of heated tobacco products	6
2.4 Recent products	10
2.4.1 Emissions	10
2.4.2 Biomarkers of exposure	11
2.5 Consumer perceptions of heated tobacco products	16
2.6 Uptake in selected markets where products are available	18
2.7 Application by Philip Morris International for status as a “modified risk tobacco product” in the USA	10
2.8 Implications for regulation and tobacco control policies	20
2.9 Recommendations for research and policy	22
2.10 References	24
3. Clinical pharmacology of nicotine in electronic nicotine delivery systems	31
3.1 Introduction	31
3.2 ENDS operations	32
3.3 Nicotine concentration in e-liquids	33
3.4 Nicotine delivery to ENDS users	35
3.5 Toxicant content of ENDS emissions	37
3.5.1 Nicotine emissions	37
3.5.2 Emissions of non-nicotine toxicants	39
3.6 Potential role of ENDS in smoking cessation	40
3.7 Potential health impact of ENDS	54
3.7.1 Behavioural trajectories associated with use of ENDS	55
3.7.2 Harm from ENDS and electronic non-nicotine delivery systems	58
3.8 Summary of evidence, research gaps and policy issues derived from the evidence	60
3.9 References	66
4. A global nicotine reduction strategy: state of the science	75
4.1 Background	75
4.2 Individual outcomes of nicotine reduction	79
4.2.1 Behavioural compensation and exposure to toxicants	79
4.2.2 Threshold for establishing or maintaining nicotine addiction	80
4.2.3 Tobacco cessation after use of VLNC cigarettes	81
4.2.4 Non-compliance in clinical trials	81

4.2.5	Adverse health effects and vulnerable populations	82
4.2.6	Summary	83
4.3	Population impact of nicotine reduction	84
4.3.1	VLNC cigarettes as replacements for regular cigarettes	85
4.3.2	Substitution of VLNC cigarettes with alternative tobacco products	86
4.3.3	The black market	88
4.3.4	Manipulation of VLNC cigarettes	89
4.3.5	Beliefs and attitudes regarding VLNC cigarettes and nicotine reduction	90
4.3.6	Summary	91
4.4	Regulatory approaches to nicotine reduction	93
4.4.1	Feasibility of nicotine reduction and potential challenges	93
4.4.2	Prerequisites for successful implementation of a nicotine reduction policy	94
4.4.3	Strategies for implementation of a nicotine reduction policy	96
4.4.4	Philosophical objections to nicotine reduction	97
4.4.5	Summary	97
4.5	Research questions	98
4.6	Policy recommendations	99
4.7	References	100
5.	A regulatory strategy for reducing exposure to toxicants in cigarette smoke	111
5.1	Introduction	111
5.2	Regulation of cigarette smoke constituents described in WHO Technical Report Series No. 951	111
5.3	Industry response to WHO Technical Report Series No. 951	114
5.4	Relation between smoke constituent levels and biomarkers	116
5.5	Use of mandated lowering of toxicant levels in a product regulatory strategy	117
5.6	Toxicants recommended for mandated lowering and recommended limits	118
5.7	Implementation of mandated lower levels of toxicants	119
5.8	Conclusions and recommendations	120
5.9	References	121
6.	The science of flavour in tobacco products	125
6.1	Introduction	125
6.2	Epidemiology of use of flavoured tobacco and nicotine products	126
6.3	Flavoured products: perceptions, experimentation, uptake and regulation	128
6.4	A brief history of the development of flavoured tobacco by the tobacco and e-cigarette industry	129
6.5	Sensory systems that contribute to flavour	131
6.6	Flavour receptors: a new science of flavour sensing and coding	133
6.7	Toxicological effects of flavours	134
6.8	Conclusions	136
6.8.1	Recommended priorities for research	137
6.8.2	Recommended policies	138
6.9	References	138
7.	Sugar content of tobacco products	143
7.1	Introduction	143
7.2	Sugars in different types of tobacco product	144
7.2.1	Types of sugars and sugar-containing additives	145

7.2.2	Amounts of sugars and sugar-containing additives	145
7.2.3	Total levels of added and endogenous sugars	146
7.2.4	Regional and cultural differences in tobacco varieties, products and use	147
7.3	Effects of sugars on levels of emissions from tobacco products	147
7.3.1	Smokeless tobacco products	147
7.3.2	Pyrolysis products of sugars and simple mixtures	148
7.3.3	Cigarettes and other combusted tobacco products	148
7.4	Effects of sugars on the toxicity of tobacco products	149
7.4.1	Smokeless tobacco	149
7.4.2	Cigarettes with and without added sugar	150
7.5	Effects of sugar on the addictiveness of tobacco products	150
7.5.1	pH and free nicotine	151
7.5.2	Formation of pharmacologically active compounds in tobacco and smoke	151
7.6	Dependence and quitting	152
7.7	Effects of sugars on the attractiveness of tobacco products	152
7.7.1	Perception: sensory characteristics	152
7.7.2	Smoking experience and behaviour: flavour, palatability, ease of inhalation, frequency of use	153
7.7.3	Initiation	153
7.8	Regulation of sugars according to jurisdiction	153
7.9	Conclusions	155
7.10	Recommendations	155
7.10.1	Further research	155
7.10.2	Policy	156
7.11	Acknowledgements	158
7.12	References	158

8. Updated priority list of toxicants in combusted tobacco products 165

8.1	Introduction	165
8.2	Background of preparation of the priority list	166
8.2.1	Criteria for selection of toxicants for the priority list	167
8.2.2	Key decisions of the Conference of the Parties on priority contents and emissions of combustible tobacco	169
8.3	Overview of new scientific knowledge on toxicity	173
8.3.1	Aldehydes (acetaldehyde, acrolein, formaldehyde, crotonaldehyde, propionaldehyde, butyraldehyde)	176
8.3.2	Aromatic amines (3-aminobiphenyl, 4-aminobiphenyl, 1-aminonaphthalene, 2-aminonaphthalene)	176
8.3.3	Hydrocarbons (benzene, 1,3-butadiene, isoprene, toluene)	176
8.3.4	Polycyclic aromatic hydrocarbons (benzo[a]pyrene)	177
8.3.5	Tobacco-specific N-nitrosamines	178
8.3.6	Alkaloids (nicotine)	179
8.3.7	Phenols (catechol, m-, p- and o-cresols, phenol, hydroquinone, resorcinol)	180
8.3.8	Other organic compounds (acetone, acrylonitrile, pyridine, quinolone)	181
8.3.9	Metals and metalloids (arsenic, cadmium, lead, mercury)	181
8.3.10	Other constituents (ammonia, carbon monoxide, hydrogen cyanide, nitrogen oxides)	183
8.4	Availability of analytical methods	183
8.4.1	Standardized WHO TobLabNet methods for the analysis of priority toxicants	183

8.4.2 Overview of methods for the remaining priority toxicants	184
8.5 Update on variations in toxicants among brands	188
8.6 Criteria for future re-evaluation of toxicants on the list	190
8.7 Criteria for selection of new toxicants	191
8.8 Research needs and regulatory recommendations	194
8.8.1 Research needs, data gaps and future work	194
8.8.2 Regulatory recommendations and support to Parties	195
8.9 References	197

9. Approaches to measuring and reducing toxicant concentrations in smokeless tobacco products 207

9.1 Introduction	207
9.2 Product composition	210
9.3 Agricultural practices and manufacturing processes that result in the formation and accumulation of harmful compounds	212
9.4 Product additives	214
9.5 Harmful agents in smokeless tobacco products and methods to reduce their effects	214
9.6 Detection of microorganisms	218
9.6.1 Rapid detection of live microorganisms by cell viability	218
9.7 Overview of analytical methods used to measure toxicants in smokeless tobacco	219
9.8 Regulatory approaches and responses	220
9.9 Policy recommendations and summary	222
9.9.1 Disclaimer	225
9.10 References	226

10. Waterpipe tobacco smoking: prevalence, health effects and interventions to reduce use 233

10.1 Introduction	233
10.2 Prevalence, health effects and effective interventions to reduce use	234
10.2.1 Regional and global patterns of waterpipe tobacco use	234
10.2.2 Acute and chronic health effects	237
10.2.3 Cultural practices and initiation and maintenance of use	239
10.2.4 Influence of flavourings	241
10.2.5 Dependence liability of low-nicotine products	242
10.2.6 Interventions	242
10.3 Future research	245

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>